Abstract | OBJECTIVE: METHODS: Sera and clinical data were collected prospectively from consecutive adult patients with polymyositis (PM; n = 134), dermatomyositis (n = 129), or other CTDs (predominantly systemic sclerosis [SSc; n = 790]). Patients were first evaluated during 1973-2001. RESULTS: Nineteen patients with the anti-SRP autoantibody were identified, 16 (84%) of whom had pure PM and 3 (2 with SSc and 1 with antisynthetase syndrome) had yet to develop features of myositis after a mean followup of 4.5 years (range 2.5-6 years). More SRP-positive PM patients had severe proximal muscle weakness (50%) and muscle atrophy (67%) at initial presentation compared with antisynthetase-positive PM controls. Cardiac involvement occurred in only 2 of 16 SRP-positive PM patients (13%), and interstitial lung disease was noted in 3 of 13 SRP-positive PM patients (23%) and in the 3 SRP-positive nonmyositis patients. There was a relative lack of inflammation in muscle biopsy specimens from the SRP-positive PM cohort. Other autoantibodies in the SRP-positive patients included Ro/SSA (4 patients), Th/To (1 patient), and anti-PL-12 (1 patient). Survival in the SRP-positive PM patients was comparable with that seen in the cohort of SRP-negative PM patients. CONCLUSION: The anti-SRP autoantibody is not specific for PM. Severe muscle weakness and atrophy were prominent features in PM patients with anti-SRP. Cardiac involvement was less common and survival was better in patients with anti-SRP than has previously been reported.
|
Authors | Amy H Kao, David Lacomis, Mary Lucas, Noreen Fertig, Chester V Oddis |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 50
Issue 1
Pg. 209-15
(Jan 2004)
ISSN: 0004-3591 [Print] United States |
PMID | 14730618
(Publication Type: Journal Article)
|
Chemical References |
- Autoantibodies
- Signal Recognition Particle
|
Topics |
- Adult
- Aged
- Antibody Specificity
- Autoantibodies
(blood)
- Dermatomyositis
(immunology, mortality, pathology)
- Female
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Muscle, Skeletal
(immunology, pathology)
- Polymyositis
(immunology, mortality, pathology)
- Scleroderma, Systemic
(immunology, mortality, pathology)
- Signal Recognition Particle
(immunology)
|